Literature DB >> 24051203

March separate, strike together--role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease.

Anne Eckert1, Rebecca Nisbet2, Amandine Grimm1, Jürgen Götz3.   

Abstract

The energy demand and calcium buffering requirements of the brain are met by the high number of mitochondria in neurons and in these, especially at the synapses. Mitochondria are the major producer of reactive oxygen species (ROS); at the same time, they are damaged by ROS that are induced by abnormal protein aggregates that characterize human neurodegenerative diseases such as Alzheimer's disease (AD). Because synaptic mitochondria are long-lived, any damage exerted by these aggregates impacts severely on neuronal function. Here we review how increased TAU, a defining feature of AD and related tauopathies, impairs mitochondrial function by following the principle: 'March separate, strike together!' In the presence of amyloid-β, TAU's toxicity is augmented suggesting synergistic pathomechanisms. In order to restore mitochondrial functions in neurodegeneration as a means of therapeutic intervention it will be important to integrate the various aspects of dysfunction and get a handle on targeting distinct cell types and subcellular compartments.
© 2013.

Entities:  

Keywords:  Alzheimer's disease; Axonal transport; DRP1; Mitochondrion; Tauopathy

Mesh:

Substances:

Year:  2013        PMID: 24051203     DOI: 10.1016/j.bbadis.2013.08.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  38 in total

Review 1.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

Review 2.  Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.

Authors:  Judit M Perez Ortiz; Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

Review 3.  Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease.

Authors:  Qian Cai; Prasad Tammineni
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 4.  Signaling pathways and posttranslational modifications of tau in Alzheimer's disease: the humanization of yeast cells.

Authors:  Jürgen J Heinisch; Roland Brandt
Journal:  Microb Cell       Date:  2016-03-25

5.  Chemotherapy accelerates age-related development of tauopathy and results in loss of synaptic integrity and cognitive impairment.

Authors:  Angie C A Chiang; Xiaojiao Huo; Annemieke Kavelaars; Cobi J Heijnen
Journal:  Brain Behav Immun       Date:  2019-04-03       Impact factor: 7.217

6.  Identification of CHCHD10 Mutation in Chinese Patients with Alzheimer Disease.

Authors:  Tingting Xiao; Bin Jiao; Weiwei Zhang; Chuzheng Pan; Jingya Wei; Xiaoyan Liu; Yafang Zhou; Lin Zhou; Beisha Tang; Lu Shen
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

Review 7.  Axonal transport defects in Alzheimer's disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2014-07-23       Impact factor: 5.590

Review 8.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

Review 9.  The Crosstalk Between Pathological Tau Phosphorylation and Mitochondrial Dysfunction as a Key to Understanding and Treating Alzheimer's Disease.

Authors:  Sanjib Guha; Gail V W Johnson; Keith Nehrke
Journal:  Mol Neurobiol       Date:  2020-08-26       Impact factor: 5.590

10.  Bryostatin-1 Restores Blood Brain Barrier Integrity following Blast-Induced Traumatic Brain Injury.

Authors:  Brandon P Lucke-Wold; Aric F Logsdon; Kelly E Smith; Ryan C Turner; Daniel L Alkon; Zhenjun Tan; Zachary J Naser; Chelsea M Knotts; Jason D Huber; Charles L Rosen
Journal:  Mol Neurobiol       Date:  2014-10-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.